Nephrectomy News and Research

RSS

Transvaginal nephrectomy could increase rate of living donors for kidney transplants

Kidney transplant from a living donor, besides of being the best option for young people and those affected by particular conditions, results in increased organ survival and solves in part the organ shortage afflicting Spain since the mid-90 despite the high rate of cadaveric donation.

5 Aug 2011

Study sheds new light on how surgery impacts chronic kidney disease, bone health

Researchers at the University of California, San Diego School of Medicine have shed new light on how surgery impacts both chronic kidney disease and bone health, particularly in women.

5 Aug 2011

Diagnostic delay in women with tuberous sclerosis complex increases mortality risk

Women with tuberous sclerosis complex (TSC) are often misdiagnosed because the condition, commonly recognized in early childhood when it presents with seizures, manifests differently later in life, typically with renal angiomyolipomas - a benign tumor of the kidney - and pulmonary lymphangioleiomyomatosis (LAM) - a rare lung disease that affects almost exclusively women.

30 Jun 2011

New data from Argos AGS-003, sunitinib Phase 2 combination study on RCC presented at ASCO

Argos Therapeutics today announced that new data from its Phase 2 combination study of its Arcelis immunotherapy for the treatment of renal cell carcinoma (RCC), AGS-003, in combination with sunitinib showed improvement over expectations for sunitinib alone in progression-free survival (PFS) in newly diagnosed metastatic RCC patients with unfavorable prognosis.

6 Jun 2011

Final analysis of AVEO's tivozanib Phase 2 trial on kidney cancer patients presented at ASCO 2011

AVEO Pharmaceuticals, Inc., today announced data from the final analysis of its Phase 2 randomized discontinuation trial evaluating tivozanib, its lead product candidate designed to optimally block the VEGF pathway by inhibiting all three VEGF receptors, in patients with advanced renal cell carcinoma.

2 Jun 2011

NewYork-Presbyterian Hospital/Weill Cornell Medical Center to present research studies at 2011 ATC

Available for expert commentary on the latest research findings presented at the 2011 American Transplant Congress in Philadelphia, April 30 to May 4, is Dr. Sandip Kapur, chief of transplant surgery and director of kidney and pancreas transplant programs at NewYork-Presbyterian Hospital/Weill Cornell Medical Center, and a leading authority on transplantation.

30 Apr 2011

Expert to present latest transplant research findings at ATC 2011

30 Apr 2011

Mary Ann Liebert introduces new videojournal on minimally invasive surgery

Videoscopy-, a groundbreaking new videojournal to complement the peer-reviewed monthly publication, Journal of Laparoendoscopic & Advanced Surgical Techniques has been launched by Mary Ann Liebert, Inc., publishers.

30 Apr 2011

UCLA's Kidney and Pancreas Transplant Program improves patients' survival rate

Patients who received kidney transplants through the UCLA Kidney and Pancreas Transplant Program had the highest three-year transplant survival rate among patients who underwent the procedure at U.S. centers that perform 80 or more transplants a year, according to new government data.

28 Apr 2011

Henry Ford performs partial nephrectomy with new, robotically controlled ultrasound probe

Henry Ford Hospital was the first hospital world-wide to use a new, robotically controlled ultrasound probe to help remove a cancerous tumor from a kidney.

6 Apr 2011

Robotic surgery offers better results than laparoscopic procedures for kidney disease

Robotic surgery offers the same or better results than minimally invasive laparoscopic procedures for treating kidney disease, and can potentially help more patients because it is not as difficult for surgeons to learn, according to a new study led by Henry Ford Hospital specialists.

2 Mar 2011

Robotic surgery offers favourable outcomes in patients with kidney disease

2 Mar 2011

Astellas, AVEO enter development, commercialization agreement for tivozanib

Astellas Pharma Inc., a global pharmaceutical company, and AVEO Pharmaceuticals, Inc. today announced that they have entered into a worldwide agreement outside of Asia to develop and commercialize tivozanib, AVEO's lead product candidate designed to optimally block the VEGF pathway by inhibiting all three VEGF receptors, for the treatment of a broad range of cancers.

17 Feb 2011

Patients with kidney tumours can benefit from nephron-sparing surgery

Patients with kidney tumours larger than four centimetres are much more likely to enjoy good long-term renal function if they undergo nephron-sparing surgery rather than radical nephrectomy, according to a study in the February issue of the urology journal BJUI.

7 Feb 2011

AVEO commences enrollment in tivozanib Phase 2 study in renal cell carcinoma

AVEO Pharmaceuticals, Inc. today announced that it has initiated patient enrollment in a multi-center Phase 2 exploratory biomarker study of tivozanib, its lead product candidate designed to optimally block the VEGF pathway by inhibiting all three VEGF receptors, in patients with renal cell carcinoma (RCC).

1 Feb 2011

AVEO third quarter total collaboration revenues increase to $6.2 million

AVEO Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced updated financial guidance and third quarter financial results, as well as recent developments.

4 Nov 2010

AVEO presents tivozanib Phase 2 study results at ESMO Congress

AVEO Pharmaceuticals, Inc. a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced that previously reported results from its Phase 2 study evaluating tivozanib for the treatment of advanced renal cell carcinoma (RCC) were presented at the 35th European Society for Medical Oncology (ESMO) Congress in Milan, Italy.

11 Oct 2010

AVEO Pharmaceuticals to present tivozanib Phase 2 study results at IKCS Symposium

AVEO Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced that previously reported results from its Phase 2 study evaluating tivozanib for the treatment of advanced renal cell carcinoma (RCC) will be presented at the Ninth International Kidney Cancer Symposium (IKCS) in Chicago, Illinois, October 1-2, 2010.

4 Oct 2010

Argos' AGS-003 in combination with sunitinib demonstrates favorable PFS for renal cell carcinoma

Argos Therapeutics announced that its Arcelis immunotherapy for renal cell carcinoma (RCC), AGS-003, demonstrated favorable progression-free survival (PFS) and safety in combination with sunitinib, based upon updated results from an ongoing Phase 2 trial.

1 Oct 2010

Results of Argos' Arcelis Phase 2 study for RCC accepted for presentation at International Kidney Cancer Symposium

Argos Therapeutics today announced that results from its Arcelis™ immunotherapy Phase 2 study for the treatment of renal cell carcinoma (RCC) have been accepted for a poster presentation at the Ninth International Kidney Cancer Symposium on Oct. 1-2 in Chicago.

24 Sep 2010

Nephrectomy News and Research

Transvaginal nephrectomy could increase rate of living donors for kidney transplants

Study sheds new light on how surgery impacts chronic kidney disease, bone health

Diagnostic delay in women with tuberous sclerosis complex increases mortality risk

New data from Argos AGS-003, sunitinib Phase 2 combination study on RCC presented at ASCO

Final analysis of AVEO's tivozanib Phase 2 trial on kidney cancer patients presented at ASCO 2011

NewYork-Presbyterian Hospital/Weill Cornell Medical Center to present research studies at 2011 ATC

Expert to present latest transplant research findings at ATC 2011

Mary Ann Liebert introduces new videojournal on minimally invasive surgery

UCLA's Kidney and Pancreas Transplant Program improves patients' survival rate

Henry Ford performs partial nephrectomy with new, robotically controlled ultrasound probe

Robotic surgery offers better results than laparoscopic procedures for kidney disease

Robotic surgery offers favourable outcomes in patients with kidney disease

Astellas, AVEO enter development, commercialization agreement for tivozanib

Patients with kidney tumours can benefit from nephron-sparing surgery

AVEO commences enrollment in tivozanib Phase 2 study in renal cell carcinoma

AVEO third quarter total collaboration revenues increase to $6.2 million

AVEO presents tivozanib Phase 2 study results at ESMO Congress

AVEO Pharmaceuticals to present tivozanib Phase 2 study results at IKCS Symposium

Argos' AGS-003 in combination with sunitinib demonstrates favorable PFS for renal cell carcinoma

Results of Argos' Arcelis Phase 2 study for RCC accepted for presentation at International Kidney Cancer Symposium

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Latest News